Janus kinases and signal transducers and activators of transcription: Their roles in cytokine signaling, development and immunoregulation

Arthritis Research

Volumn 2, Issue 1, 2000, Pages 16-32

  Ortmann, R A ^a   Cheng, T ^a   Visconti, R ^a   Frucht, D M ^a   O'Shea, J J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cytokines; Immunoregulation; Jak; Signaling; Stat

Indexed keywords

CYTOKINE; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE 4; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; UNCLASSIFIED DRUG;

DEVELOPMENT; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MEDIATOR; MEDICAL RESEARCH; MOUSE; NONHUMAN; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; HUMANS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 0034468138     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar66     Document Type: Review

References (238)

1. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
2. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs)
3. Signaling by the cytokine receptor superfamily
4. Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?
5. The IFN-gamma receptor: A paradigm for cytokine receptor signaling
6. Jaks and STATs: Biological implications
7. Signaling via JAK tyrosine kinases: Growth hormone receptor as a model system
8. Janus kinases and their role in growth and disease
9. STATs as mediators of cytokine-induced responses
10. Negative regulation of the JAK/STAT pathway
11. Negative regulators of cytokine signal transduction
12. The role of cytokine receptor signaling in lymphocyte development
13. Identification and chromosomal mapping of new human tyrosine kinase genes
14. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase
15. JAK2, a third member of the JAK family of protein tyrosine kinases
16. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes
17. Molecular cloning of a chicken JAK homolog from activated T cells
18. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects
19. Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila
20. Signaling through the hematopoietic cytokine receptors
21. A protein tyrosine kinase in the interferon alpha/beta signaling pathway
22. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway
23. Interferon-induced nuclear signalling by Jak protein tyrosine kinases
24. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin
25. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase
26. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells
27. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2
28. The Janus protein tyrosine kinase family and its role in cytokine signaling
29. Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells
30. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor
31. Regulation of JAK3 expression and activation in human B cells and B cell malignancies
32. Regulation of JAK3 expression in human monocytes: Phosphorylation in response to interleukins 2, 4, and 7
33. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: Implications for XSCID and XCID
34. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits
35. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor
36. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways
37. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction
38. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
39. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development
40. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans
41. Defective lymphoid development in mice lacking Jak3
42. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3
43. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice
44. The role of Jak3 in lymphoid development, activation, and signaling
45. Interleukin-7 (IL-7) knockout mice. Implications for lymphopoiesis and organ-specific immunity
46. Impaired survival and proliferation in IL-7 receptor-deficient peripheral T cells
47. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine
48. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency
49. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
50. Structural and functional basis for JAK3-deficient severe combined immunodeficiency
51. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta
52. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment
53. Functional dissection of the cytoplasmic subregions of the IL-2 receptor betac chain in primary lymphocyte populations
54. Crucial role of Jak3 in negative selection of self-reactive T cells
55. Development of autologous, oligoclonal, poorly functioning T lymphocytes in a patient with autosomal recessive severe combined immunodeficiency caused by defects of the Jak3 tyrosine kinase
56. Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene
57. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase
58. The human interferon alpha/beta receptor: Characterization and molecular cloning
59. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta
60. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction
61. JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region
62. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components
63. Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases
64. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses
65. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
66. Jak2 is essential for signaling through a variety of cytokine receptors
67. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
68. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
69. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells
70. Role of JAK3 in CD40-mediated signaling
71. JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells
72. A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells
73. Crystal structure of the tyrosine kinase domain of the human insulin receptor
74. Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase
75. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop
76. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity
77. Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling
78. Identification of SH2-bbeta as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2
79. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase
80. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways
81. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT
82. Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor
83. The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain
84. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses
85. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals
86. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: Mapping of the Jak3-receptor interaction domain
87. Definition of the interferon-alpha receptor-binding domain on the TYK2 kinase
88. Specific contribution of tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1
89. STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction
90. Hrs is associated with STAM, a signal-transducing adaptor molecule. Its suppressive effect on cytokine-induced cell growth
91. Possible involvement of a novel STAM-associated molecule "AMSH" in intracellular signal transduction mediated by cytokines
92. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation
93. Erythropoietin receptor activation by a ligand-induced conformation change
94. The stress-activated protein kinase pathways
95. Signal transduction from the B cell antigen-receptor
96. The IL-4 receptor: Signaling mechanisms and biologic functions
97. Genetic analysis of B cell antigen receptor signaling
98. Activation and signal transduction via mitogen-activated protein (MAP) kinases in T lymphocytes
99. Mitogen-activated protein kinase cascades and regulation of gene expression
100. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction
101. Activation of transcription by IFN-gamma: Tyrosine phosphorylation of a 91-kD DNA binding protein
102. Stat3 and Stat4: Members of the family of signal transducers and activators of transcription
103. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway
104. Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation
105. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis
106. An interleukin-4-induced transcription factor: IL-4 Stat
107. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response
108. Identification and purification of human Stat proteins activated in response to interleukin-2
109. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue
110. STATs and gene regulation
111. Proteins of transcription factor ISGF-3: One gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha
112. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma
113. Stat recruitment by tyrosine-phosphorylated cytokine receptors: An ordered reversible affinity-driven process
114. Components of a Stat recognition code: Evidence for two layers of molecular selectivity
115. Three-dimensional structure of the Stat3beta homodimer bound to DNA
116. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA
117. Structure of the amino-terminal protein interaction domain of STAT-4
118. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain
119. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6
120. The significance of tetramerization in promoter recruitment by Stat5
121. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha
122. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling
123. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300
124. Transcription factor-specific requirements for coactivators and their acetyltransferase functions
125. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5- mediated suppression of the response
126. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling
127. Functional interactions between Stat5 and the glucocorticoid receptor
128. Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells
129. Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells
130. Stat1 depends on transcriptional synergy with Sp1
131. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3
132. Interaction of stat6 and NF-kappaB: Direct association and synergistic activation of interleukin-4-induced transcription
133. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
134. Requirement of serine phosphorylation for formation of STAT-promoter complexes
135. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3
136. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma
137. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype
138. Activation of STAT4 by IL-12 and IFN-alpha: Evidence for the involvement of ligand-induced tyrosine and serine phosphorylation
139. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway
140. Differential control of the phosphorylation state of proline-juxtaposed serine residues ser725 of stat5a and ser730 of stat5b in prolactin-sensitive cells
141. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, sub-cellular redistribution, and functional inhibition of STAT3
142. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3
143. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in stat3 transcriptional activity induced by the src oncoprotein
144. The mitogen-activated protein (MAP) kinase p38 and its upstream activator MAP kinase kinase 6 are involved in the activation of signal transducer and activator of transcription by hyperosmolarity
145. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons
146. Serine phosphorylation and negative regulation of stat3 by JNK
147. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins
148. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation
149. Rapid inhibition of interleukin-6 signaling and stat3 activation mediated by mitogen-activated protein kinases
150. Amino-terminal signal transducer and activator of transcription (STAT) domains regulate nuclear translocation and STAT deactivation
151. Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4
152. Nuclear import and export of proteins: The molecular basis for intracellular signaling
153. Nuclear export receptors: From importin to exportin
154. Transport into and out of the cell nucleus
155. The carboxyl terminus of interferon-gamma contains a functional polybasic nuclear localization sequence
156. Hypothesis: Ligand/receptor-assisted nuclear translocation of STATs
157. Interferon gamma receptor deficient mice are resistant to endotoxic shock
158. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease
159. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
160. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection
161. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway
162. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
163. Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of stat1
164. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases
165. Type I interferons are essential mediators of apoptotic death in virally infected cells
166. Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA
167. Targeted disruption of the mouse Stat3 gene leads to early 'embryonic' lethality
168. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation
169. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils
170. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells
171. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice
172. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses
173. Characterization of IL-12 receptor beta1 chain (IL-12Rbeta1)-deficient mice: IL-12Rbeta1 is an essential component of the functional mouse IL-12 receptor
174. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients
175. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells
176. Stat5a is mandatory for adult mammary gland development and lactogenesis
177. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression
178. STAT5a and STAT5b proteins have essential and nonessential, or redundant, roles in cytokine responses
179. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells
180. An indirect effect of Stat5a in IL-2-induced proliferation: A critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction
181. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity
182. -/- mice: A direct role for Stat5 in Bcl-X(L) induction
183. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes
184. STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation
185. Cutting edge: TCR stimulation by antibody and bacterial superantigen induces stat3 activation in human T cells
186. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells
187. Essential role of Stat6 in IL-4 signalling
188. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice
189. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene
190. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice
191. Signal transducer and activator of transcription factor 6 (Stat6)- deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production
192. Analysis of cytokine signaling in patients with extrinsic asthma and hyperimmunoglobulin E
193. STAT6 deficiency in a mouse model of allergen-induced airways inflammation abolishes eosinophilia but induces infiltration of CD8+ T cells
194. Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response
195. STAT6-deficient mice exhibit normal induction of murine AIDS and expression of immunoglobulin E following infection with LP-BM5 murine leukemia viruses
196. A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells
197. T cell antigen receptor signal transduction pathways
198. STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1
199. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6
200. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor
201. Activation of the STAT pathway by angiotensin II in T3CHO/AT1A cells. Cross-talk between angiotensin II and interleukin-6 nuclear signaling
202. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor
203. The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor
204. SH2 signaling in a lower eukaryote: A STAT protein that regulates stalk cell differentiation in dictyostelium
205. Evidence that the Dictyostelium Dd-STATa protein is a repressor that regulates commitment to stalk cell differentiation and is also required for efficient chemotaxis
206. Stat3 activation is required for cellular transformation by v-src
207. Stat3 as an oncogene
208. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals
209. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction
210. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells
211. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene
212. Identification of PTP1C mutation as the genetic defect in motheaten and viable motheaten mice: A step toward defining the roles of protein tyrosine phosphatases in the regulation of hemopoietic cell differentiation and function
213. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene
214. Motheaten, an immunodeficient mutant of the mouse. I. Genetics and pathology
215. The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: Increased resorption and osteopenia in me(v)/me(v) mutant mice
216. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway
217. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors
218. A family of cytokine-inducible inhibitors of signalling
219. A new protein containing an SH2 domain that inhibits JAK kinases
220. Structure and function of a new STAT-induced STAT inhibitor
221. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
222. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain
223. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice
224. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1
225. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine
226. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality
227. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling
228. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation
229. SOCS3 is essential in the regulation of fetal liver erythropoiesis
230. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling
231. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice
232. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling
233. Cis desensitizes GH induced Stat5 signaling in rat liver cells
234. Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor
235. Inhibition of Stat1-mediated gene activation by PIAS1
236. Specific inhibition of Stat3 signal transduction by PIAS3
237. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation
238. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6